Summary:
The use of enteral antibiotics to prevent acute graft versus host disease (GvHD) has not been studied prospectively in children. We hypothesized the risk of GvHD in pediatric bone marrow transplant (BMT) recipients would be decreased with enteral metronidazole. Eligible subjects included pediatric patients referred to one center for first allogeneic BMT. Enteral metronidazole 20 mg/kg/day divided thrice daily (maximum 750 mg/day) was administered from day −14 to day +35. The risk of GvHD grade II or more severe among subjects treated with metronidazole was compared to historical controls. There were no significant differences between treated (n=19) and historical controls (n=83) with respect to age, gender, prophylaxis, or conditioning regimens, proportion receiving unrelated donor marrow, proportion receiving umbilical cord blood, or transplantation indication. The probability of remaining free of GvHD at day +100 was lower in the treated group (P=0.047). The adjusted relative risk of developing GvHD among subjects treated with metronidazole was 0.36 (95% CI: 0.13–0.997; P=0.05). Five patients were unable to complete the study; two were likely related to study medication. We conclude that enteral metronidazole appears effective in the prevention of GvHD. These results suggest that a randomized trial is justifiable in children, especially recipients of alternative donor BMT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.
Filipovich AH, Vallera DA, Youle RJ et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62–69.
Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77–82.
Weisdorf D, Filipovich A, McGlave P et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant 1993; 12: 531–536.
Bekkum DWv, Roodenburg J, Heidt PJ, Waaij Dvd . Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401–404.
Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668–2676.
Beelen DW, Elmaagacli A, Muller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267–3275.
Grove D, Mahmoud A, Warren K . Suppression of cell-mediated immunity by metronidazole. Int Archs Allergy Appl Immun 1977; 54: 422–427.
Tanga MR, Antani JA, Kabade SS . Clinical evaluation of metronidazole as an anti-inflammatory agent. Int Surg 1975; 60: 75–76.
Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302–307.
Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071–1075.
Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550–562.
Freston J . Looking for hepatotoxicity, working up patients, and assessing causality. In: Drug-Induced Liver Injury: A National and Global Problem 12–13 February 2001, Westfields Conference Center, Chantilly, VA; 2001; Westfields Conference Center, Chantilly, VA: Food and Drug Administration, 2001.
Hill GR, Ferrara JL . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–2759.
Hill GR, Krenger W, Ferrara JL . The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther 1997; 3: 257–266.
Ganrot-Norlin K, Stalhandske T, Karlstrom R . Lack of antiinflammatory activity of metronidazole. Acta Pharmacol Toxicol (Copenh) 1981; 49: 130–133.
Duffy LF, Daum F, Fisher SE et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 681–684.
Bradley WG, Karlsson IJ, Rassol CG . Metronidazole neuropathy. Br Med J 1977; 2: 610–611.
Acknowledgements
The authors wish to thank the BMT physicians at CCHMC who cared for the patients in this study: Drs Thomas G Gross, Brett Loechelt, Michael Boyer, Jane Sande and Richard Harris. We would also like to thank Drs Mitchell B Cohen, Beverly L Connelly, and Brett Loechelt for serving as members of the Data Safety Monitoring Board.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guthery, S., Heubi, J. & Filipovich, A. Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: results of a pilot study. Bone Marrow Transplant 33, 1235–1239 (2004). https://doi.org/10.1038/sj.bmt.1704474
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704474